|
End-of-day quote
Taipei Exchange
2026-10-02
|
5-day change | 1st Jan Change | ||
| 55.40 TWD | +0.18% |
|
-0.18% | -21.31% |
Company Valuation: PharmaEngine, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 8,430 | 10,207 | 17,961 | 15,158 | 12,974 | 10,115 |
| Change | - | 21.08% | 75.96% | -15.6% | -14.41% | -22.04% |
| Enterprise Value (EV) 1 | 5,058 | 6,401 | 14,322 | 11,545 | 9,120 | 5,440 |
| Change | - | 26.55% | 123.74% | -19.39% | -21% | -40.35% |
| P/E | 14x | 24.7x | 56.3x | 55.2x | 7.42x | 26.2x |
| PBR | 2.1x | 2.65x | 4.64x | 3.92x | 2.4x | 2.05x |
| PEG | - | -0.9x | -2.3x | -4x | 0x | -0.3x |
| Capitalization / Revenue | 7.98x | 15.6x | 27.4x | 19.7x | 5.14x | 11.1x |
| EV / Revenue | 4.79x | 9.78x | 21.9x | 15x | 3.61x | 5.97x |
| EV / EBITDA | 6.24x | 17.6x | 50.5x | 41.4x | 4.44x | 12.7x |
| EV / EBIT | 6.25x | 17.6x | 50.7x | 41.7x | 4.44x | 12.8x |
| EV / FCF | -100x | 8.84x | 136x | 72.2x | -464x | 3.36x |
| FCF Yield | -1% | 11.3% | 0.74% | 1.38% | -0.22% | 29.7% |
| Dividend per Share 2 | 2.535 | 2.7 | 2 | 1.5 | 6 | 2 |
| Rate of return | 4.38% | 3.72% | 1.6% | 1.42% | 6.64% | 2.84% |
| EPS 2 | 4.14 | 2.94 | 2.22 | 1.91 | 12.17 | 2.69 |
| Distribution rate | 61.2% | 91.8% | 90.1% | 78.5% | 49.3% | 74.3% |
| Net sales 1 | 1,056 | 654.8 | 654.4 | 767.7 | 2,523 | 911.4 |
| EBITDA 1 | 811.3 | 363.4 | 283.4 | 278.5 | 2,055 | 427.2 |
| EBIT 1 | 809.7 | 362.7 | 282.7 | 277.2 | 2,053 | 425.5 |
| Net income 1 | 604.3 | 426 | 318.8 | 274.6 | 1,751 | 387.6 |
| Net Debt 1 | -3,372 | -3,806 | -3,639 | -3,613 | -3,854 | -4,675 |
| Reference price 2 | 57.90 | 72.60 | 125.00 | 105.50 | 90.30 | 70.40 |
| Nbr of stocks (in thousands) | 145,597 | 140,596 | 143,687 | 143,679 | 143,678 | 143,678 |
| Announcement Date | 3/24/21 | 3/18/22 | 3/17/23 | 3/12/24 | 3/7/25 | 3/21/26 |
1TWD in Million2TWD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 250M | |
| 21.73x | 7.71x | 15.48x | 1.37% | 74.16B | |
| 29.82x | 8.57x | 26.7x | 0.04% | 57.39B | |
| 32.98x | 5.93x | 17.77x | 0.98% | 47.64B | |
| -21.31x | 230.81x | -22.97x | -.--% | 44.29B | |
| 33.26x | 3.23x | 13.97x | -.--% | 42.5B | |
| 46.77x | 5.41x | 29.66x | -.--% | 40.71B | |
| 27.63x | 7.93x | 20.48x | 0.41% | 30.97B | |
| 32.99x | 7.05x | 18.3x | -.--% | 28.53B | |
| -15.1x | 5.68x | -7.14x | -.--% | 24.34B | |
| Average | 20.98x | 31.37x | 12.47x | 0.31% | 39.08B | |
| Weighted average by Cap. | 22.27x | 32.04x | 13.55x | 0.42% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- 4162 Stock
- Valuation PharmaEngine, Inc.
Select your edition
All financial news and data tailored to specific country editions
